

Iowa Medicaid Pharmaceutical and Therapeutics Committee Minutes

Date: August 18, 2022

Chairperson: Mark Graber, M.D.

Erin Halverson, IME staff, assisted in running the meeting with the Chairperson due to the virtual format.

Time: 9:34 a.m. to 11:19 a.m.

Location: WebEx Teleconference (due to Federal PHE Declaration for the COVID-19 Pandemic)

Due to the current federal state of emergency, continually fluctuating numbers of coronavirus cases in various counties, the need for stability and pre-planning for the public, and due to increased workload of our members directly related to the COVID-19 pandemic, the Committee finds that it is impossible/impractical to meet in person for the August 18, 2022 meeting, and that it must be held electronically.

Committee Members Present: Mark Graber, M.D.; Charles Wadle, D.O.; Abby Cate, Pharm.D.; Jason Kessler, M.D.; Tricia White, R.N.; and Mylo Wells, Pharm.D. (Vacancies July 2021: 1 Physician, 1 Physician Assistant)

Iowa DHS Staff Present: Susan Parker, Pharm.D., Pharmacy Consultant.

Iowa Medicaid Enterprise (IME) Staff Present: Jacquelyn Hedlund, M.D., MS; Ryan Fell, Pharm.D.; Erin Halverson, R.Ph.; Gina Kuebler, R.Ph.; Pam Smith, R.Ph.; and Melissa Biddle.

Managed Care Organization (MCO) Staff Present: Lisa Todd, Amerigroup Iowa; and Emily Rogers, Iowa Total Care.

Chairperson Mark Graber called the meeting to order.

- I. Mark Graber asked that each committee and DHS and IME staff member introduce themselves to the public. Abby Cate made the motion to approve the April minutes, and Mylo Wells seconded. The motion passed with no objections. There were no new verbal conflict of interest disclosures.
- II. PDL Revision Notifications (Erin Halverson): The fax blasts sent to providers since the last P&T Meeting in April, to notify them of preferred drug list changes, were reviewed. There were three of them, for Epogen, Adderall XR, and Proventil HFA, due to availability issues for Retacrit and amphetamine-dextroamphetamine ER capsules and the discontinuation of ProAir HFA.
- III. Drug Rebate Issues (Dr. Fell): The Inflation Reduction Act recently passed gives Medicare the ability to negotiate on high cost drugs, but will not impact Medicaid or Medicaid rebates. Within that bill, however, there was a provision that looked at capping insulin costs. It was removed from the bill, but is now in consideration as a stand-alone bill, and could potentially cap list prices on insulin products in the commercial space starting in 2023, possibly affecting Medicaid rebates in the process, depending which manufacturers participate and where the price caps are set.

- IV. PA Criteria/Pro-DUR Edits (Dr. Parker): Susan Parker reviewed the informational letters that had been sent out since the last P&T Meeting in April, all posted online at http://iowamedicaidpdl.com/informational_letters and http://iowamedicaidpos.com/latest_news. Providers received Informational Letters 2337-MC-FFS and 2352-MC-FFS related to PDL and prior authorization criteria changes that went into effect June 1, 2022, and August 1, 2022, respectively, following the April P&T and May DUR Meetings. The committee also received copies of the letters sent to the Department of Human Services from the DUR Commission after their May and August meetings, which included recommendations for: PCSK9 Inhibitors; Finerenone (Kerendia); Odevixibat (Bylvay); Pegcetacoplan (Empaveli); Tasimelteon (Hetlio); Janus Kinase Inhibitors; Tralokinumab-Idrm (Adbry); Crisaborole (Eucrisa); Extended-Release Formulations; Non-Preferred Drug; Biologicals for Hidradenitis Suppurativa; and Ophthalmic Agents for Presbyopia. Also included were details regarding proposed ProDUR edits for Initial Days' Supply Limit – Benzodiazepines; Benzodiazepine Cumulative Quantity Limit; and quantity limits for select drugs.
- V. Legislation (Dr. Parker): There were no additional updates to those Ryan Fell mentioned above.
- VI. IME Updates (Dr. Parker): The final July 2022 cost of dispensing report is available on the reimbursement section of the website. The report showed the mean cost of dispensing as \$10.97 per prescription for all pharmacies including specialty, and \$10.18 for all non-specialty pharmacies. The current dispensing fee of \$10.38 will remain in place until additional state funding is appropriated in the next Iowa legislative session, and a state plan amendment would also have to be submitted to CMS for approval. Any change would be prospective following approval.
- VII. Public Comment: As this meeting was purely virtual, only written public comment was accepted. The committee members reviewed the received comments, which are posted at: <http://www.iowamedicaidpdl.com/public-comments>. They were also forwarded manufacturer comments as they were received via email prior to the meeting.

Provider Comments Received:
Invega Hafyera

Manufacturer Comments Received:
Pyrukynd, Vijoice, Tresiba, Ozempic, Rybelsus, Saxenda, Wegovy, Caplyta, Vonjo

At 9:48, Abby Cate motioned to go to closed session as authorized by Iowa Code Section 21.5(1)(a) of the Open Meetings Law to review or discuss economic records associated with the PDL which are required or authorized to be kept confidential. The motion passed with unanimous roll call approval. Open session resumed at 10:31.

- VIII. PDL Discussion and Deliberation (Erin Halverson): All subsequent recommendations (with numbering as provided on agenda attachment 2) were made to maximize cost savings to the program unless otherwise noted.
1. Vimpat tablets to Non-Preferred (grandfather established users with seizure diagnosis).

Abby Cate motioned to accept the recommendations above, and Mylo Wells seconded. The decision was unanimous.

- IX. Newly Released Drugs (Dr. Hedlund): All following recommendations (with numbering as provided on agenda attachment 3) were made to maximize cost savings to the program unless otherwise noted. Complete new drug monographs can be found on the August meeting page at http://iowamedicaidpdl.com/schedule_page/august-18-2022. Dr. Hedlund reviewed the new drugs, and the recommendations were as follows:

1. Besremi- Recommend status on the RDL as Recommended with Conditions
2. Cinqo- Recommend status on the PDL as Non-Preferred with Conditions
3. Ibsrela- Recommend status on the PDL as Non-Preferred with Conditions
4. Pyrukynd- Recommend status on the PDL as Non-Preferred
5. Tarpeyo- Recommend status on the PDL as Non-Preferred
6. Vioice- Recommend status on the PDL as Non-Preferred
7. Vonjo- Recommend status on the RDL as Non-Recommended with Conditions

Mylo Wells motioned to accept the recommendations above, and Chuck Wadle seconded. The decision was unanimous.

- X. Newly Released Generic Drugs (Erin Halverson): All following recommendations were made to maximize cost savings to the program unless otherwise noted.

Drug Name	PDL/RDL Recommendation
Apomorphine	Non-Preferred
Bexarotene Gel	Non-Preferred
Cyclobenzaprine Caps	Non-Preferred with Conditions
Cyclosporine Ophth Emulsion	Non-Preferred
Diclofenac Potassium Caps	Non-Preferred with Conditions
Fluticasone Propionate HFA	Non-Preferred
Fluticasone / Vilanterol	Non-Preferred
Isosorbide / Hydralazine	Non-Preferred
Lacosamide	Preferred
Lenalidomide	Non-Preferred with Conditions
Levamlodipine	Non-Preferred
Maraviroc	Non-Preferred
Metformin Oral Solution	Non-Preferred
Nalmefene Injection	Non-Preferred
Pirfenidone	Non-Preferred with Conditions
Potassium Iodide Oral Solution	Preferred

Mylo Wells motioned to accept the recommendations above. Chuck Wadle seconded, and all members were in favor.

- XI. New Drug Dosage Forms/Strengths/Combinations/BioSimilar (Erin Halverson): All following recommendations were made to maximize cost savings to the program unless otherwise noted.

Drug Name	PDL/RDL Recommendation
Baclofen Oral Solution	Non-Preferred with Conditions
Dartisla	Non-Preferred with Conditions
Epsolay	Non-Preferred with Conditions
Fleqsuvy	Non-Preferred with Conditions
Invega Hafyera	Non-Preferred Step 3
Lyvispah	Non-Preferred with Conditions
Norliqva	Non-Preferred with Conditions
Releuko	Non-Preferred with Conditions
Seglentis	Non-Preferred with Conditions
Tlando	Non-Preferred with Conditions
Tramadol Oral Solution	Non-Preferred with Conditions
Twynéo	Non-Preferred with Conditions
Zimhi	Non-Preferred

Abby Cate motioned to accept the recommendations above. Mylo Wells seconded, and all members were in favor.

- XII. Drug Safety Presentation (Dr. Hedlund): A PowerPoint outlining the Code of Federal Regulations, fast track approval process, drug withdrawals, current drug safety communications, and withdrawn accelerated approval drugs was presented.

A motion was made by Abby Cate to adjourn the meeting. It was seconded by both Mylo Wells and Jason Kessler, and all in attendance approved. The meeting adjourned at 11:19 a.m. The next scheduled meeting is tentatively set for November 17, 2022.